Clinical Trial Compares Cardiovascular Risks of Febuxostat and Allopurinol for Gout Treatment

Understanding Gout and Its Causes

A recent study published in the New England Journal of Medicine (NEJM) examined the cardiovascular risks associated with febuxostat and allopurinol, two medications used for treating gout. Gout is a form of arthritis that arises from the accumulation of urate crystals in the joints, often due to disturbances in uric acid metabolism. Uric acid, typically excreted by the kidneys, can accumulate in the body, leading to painful symptoms such as sudden pain, swelling, redness, and tenderness in the affected joints.

Current Treatments and Cardiovascular Risks

Various uric-acid-lowering medications, including allopurinol, febuxostat, and probenecid, are commonly prescribed for gout management. Patients with gout are also believed to be at an increased risk for cardiovascular diseases. The recent clinical trial aimed to determine whether the use of febuxostat is associated with a higher cardiovascular risk compared to allopurinol.

Trial Methodology and Patient Demographics

The trial involved over 6,000 patients from more than 320 centers across North America, with participants followed for an average of 32 months. Patients were treated with either 40-80 mg of febuxostat or 200-600 mg of allopurinol. The primary objective of the study was to evaluate the frequency of cardiovascular events between the two groups.

Key Findings

The results of the study revealed that the overall incidence of cardiovascular events did not show significant differences between the two treatment groups. Specifically, the incidence of cardiovascular risk in the allopurinol group was 10.8%, while the febuxostat group reported a corresponding rate of 10.4%. However, the study noted a higher rate of fatalities due to cardiovascular events in the febuxostat group, with 4.3% compared to 3.2% in the allopurinol group.

Study Limitations and Additional Observations

The authors of the study highlighted a significant limitation: the loss of follow-up patients in both groups, which could potentially influence the study’s outcomes. Additionally, interactions with other nonsteroidal anti-inflammatory drugs (NSAIDs) were identified, warranting further investigation.

Conclusion

In summary, the study concluded that patients with gout treated with febuxostat experienced similar rates of major cardiovascular events compared to those treated with allopurinol. However, the findings indicated an increased incidence of all-cause mortality associated with febuxostat.

Reference

White WB, Saag KG, Becker MA, et al. Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout. NEJM. 2018 March 12.

Author

Written by Vinayak Khattar, Ph.D., M.B.A.